Sandra Swain, MD, FASCO, of the Georgetown University Medical Center, Washington, DC, discusses the SAFE-HEaRt (NCT01904903) study which provides safety data of HER2-targeted therapies in patients with breast cancer and reduced LVEF while receiving cardioprotective medications and close cardiac monitoring. This interview was held at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.